Drug Delivery Systems: Entering the Mainstream

Theresa M. Allen(University of British Columbia), Pieter R. Cullis(University of British Columbia)
Science
March 19, 2004
10.1126/science.1095833
Cited by 4,500

Abstract

Drug delivery systems (DDS) such as lipid- or polymer-based nanoparticles can be designed to improve the pharmacological and therapeutic properties of drugs administered parenterally. Many of the early problems that hindered the clinical applications of particulate DDS have been overcome, with several DDS formulations of anticancer and antifungal drugs now approved for clinical use. Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs derived from proteomics or genomics research and for their use in ligand-targeted therapeutics.

Related Papers

Transport of molecules across tumor vasculature
Rakesh K. Jain|Cancer and Metastasis Reviews|1987|863
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer
Gerald Batist, Gopal Ramakrishnan, Chandra Sekhar Rao et al.|Journal of Clinical Oncology|2001|658
Brain drug delivery of small molecules using immunoliposomes
Jörg Huwyler, Dafang Wu, William M. Pardridge|Proceedings of the National Academy of Sciences|1996|649
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Elise A. Olsen, Madeleine Duvic, Arthur E. Frankel et al.|Journal of Clinical Oncology|2001|610
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.
Beatrice Uziely, Susan Jeffers, Rut Isacson et al.|Journal of Clinical Oncology|1995|477